Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Huazhong University of Science and Technology
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07591597CT.gov A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07502014CT.gov A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07124858CT.gov Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07446465CT.gov FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07235293CT.gov A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | — | Recruiting | — | — | — |
NCT07150403CT.gov Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07229872CT.gov A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment | — | Not Yet Recruiting | — | — | — |
NCT06856837CT.gov - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | — | Recruiting | — | — | — |
NCT06992258CT.gov A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07011576CT.gov A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) | — | Recruiting | — | — | — |
Show 41 more trialsShow fewer
NCT07136077CT.gov A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT07284992CT.gov SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | — | Recruiting | — | — | — |
NCT07071714CT.gov A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer | — | Recruiting | — | — | — |
NCT06963502CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06562543CT.gov A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | — | Recruiting | — | — | — |
NCT06497985CT.gov A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT04516681CT.gov Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06825624CT.gov ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06551207CT.gov Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC | — | Recruiting | — | — | — |
NCT06513221CT.gov A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | — | Not Yet Recruiting | — | — | — |
NCT06484153CT.gov Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06218888CT.gov A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT06441565CT.gov Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | — | Recruiting | — | — | — |
NCT06373133CT.gov SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06347198CT.gov Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06231017CT.gov Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer | — | Unknown | — | — | — |
NCT06765616CT.gov Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT06543836CT.gov ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer | — | Recruiting | — | — | — |
NCT06118762CT.gov Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05993702CT.gov TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05954429CT.gov A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | — | Recruiting | — | — | — |
NCT06168786CT.gov Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC | — | Recruiting | — | — | — |
NCT05771181CT.gov Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT05634590CT.gov The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05565417CT.gov Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05447715CT.gov Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05435313CT.gov Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | — | Unknown | — | — | — |
NCT05368805CT.gov Fruquintinib DDI Study With P-gp and BCRP Substrates | — | Completed | — | — | — |
NCT05511051CT.gov A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | — | Unknown | — | — | — |
NCT04948034CT.gov The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | — | Unknown | — | — | — |
NCT04577963CT.gov A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04296019CT.gov Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06202417CT.gov Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study | — | Completed | — | — | — |
NCT05025631CT.gov A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） | — | Completed | — | — | — |
NCT04322539CT.gov A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04431791CT.gov Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer | — | Unknown | — | — | — |
NCT04179084CT.gov Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer | — | Unknown | — | — | — |
NCT03977090CT.gov Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02314819CT.gov A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) | — | Completed | — | — | — |
NCT02196688CT.gov Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01975077CT.gov A Phase Ib Study of Fruquintinib in 3rd Line mCRC | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adebrelimab (this asset) | Huazhong University of Science and Technology | Approved | BB · 67 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Adebrelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
| Malignant Pancreatic Neoplasm | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adebrelimab in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adebrelimab-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →